PROs In Diabetes: FDA Panel Wanted Data Proving Insulin Icodec’s ‘Theoretical’ Benefits In Type 1

Patient-reported diabetes treatment satisfaction questionnaire used in Novo Nordisk’s ONWARDS 6 study had methodological shortcomings, US FDA said. Without reliable PRO data, benefits from a once-weekly injection remained theoretical, while hypoglycemia risks were real, panelists said.